Our results demonstrated that RBM38 deactivation could promote HCC tumorigenesis and progression via promoting mdm2, consequently inhibiting p53 and finally disrupting the p53-mdm2 loop function at the posttranscriptional level despite that amounts of p53 and mdm2 transcripts were stable. Here, MDM2 is linked to hepatocellular carcinoma.